BiotechTube
Home/Pipeline/Cardiac Cell Therapy Program

Cardiac Cell Therapy Program

Heart Failure

Pre-clinicalActive

Key Facts

Indication
Heart Failure
Phase
Pre-clinical
Status
Active
Company
StemCardia

About StemCardia

StemCardia is a private, pre-clinical stage biotech focused on pioneering heart regeneration therapies using engineered pluripotent stem cell-derived cardiac muscle cells. The company is built upon decades of foundational research from its scientific founders, including landmark studies in primates demonstrating functional benefit. StemCardia is advancing a pipeline of cell and gene therapies through strategic academic and industry partnerships, positioning itself to tackle the massive and growing burden of heart failure.

View full company profile

Therapeutic Areas

Cardiovascular DiseaseHeart Failure

Other Heart Failure Drugs

DrugCompanyPhase
NTP42ATXA TherapeuticsPreclinical
Heart Failure TrialClinical Investigation SpecialistsNot Specified
INPEFA (sotagliflozin)Lexicon PharmaceuticalsApproved
MyCardia™Avery TherapeuticsPre-clinical
Cardiac Assist DeviceSecond Heart AssistPre-clinical
Isosorbide Dinitrate/Hydralazine HCl Tabletsi3 PharmaceuticalsApproved
TLT-101TikkunLev TherapeuticsPre-clinical
Undisclosed Heart Regeneration ProgramAnimatus BiosciencesPre-clinical
AFteR RegistryOcclutechN/A (Registry)
biotx.ai Target Discovery CollaborationHeartBeat.bioPre-clinical
SurlorianRyCarma TherapeuticsPhase 2
Coronary Sinus ReductionShockwave MedicalUnknown